While independent preclinical studies have reported beneficial effects of glutamate-oxaloacetate transaminase (GOT) in models of ischemic stroke, these findings remain dispersed across the literature. This PRISMA-compliant systematic review and meta-analysis aims to combine data from these studies to determine GOT’s therapeutic potential in ischemic stroke, focusing on the effects on lesion size and neurofunctional deficit. After screening results from searches in PubMed and Web of Science, and citation chasing, 12 eligible studies were included. Range of evidence met nine out of 13 STAIR criteria. Median (Q1, Q3) quality score was 8.5 (6, 11.25) on the CAMARADES 15-item checklist. Both endogenous GOT up-regulation and exogenous GOT administration reduced infarct size, with SMD = 1.14 (95% CI 0.61–1.67; p < 0.0001), to a higher extent in mice than in rats. GOT interventions also improved edema, neuronal death, somatosensory evoked responses and neurofunctional score. The findings support the therapeutic potential of GOT for acute stroke. However, effect sizes were substantially reduced after publication bias correction (28% reduction for infarct size, with some functional outcomes losing significance), and the complete absence of female, aged, and comorbid animals limits clinical translation. High-quality, pre-registered studies in clinically relevant populations are essential before clinical trials.
• The therapeutic potential of glutamateoxaloacetate transaminase (GOT) in ischemic stroke was systematically reviewed and meta-analyzed.
FeiginVLAbateMDAbateYH, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol2024; 23: 973–1003.
2.
PrabhakaranSGonzalezNRZachrisonKS, et al. 2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke2026; 57. Epub ahead of print 2026.
3.
HirschSKostevKTanislavC, et al. Acute ischemic stroke treatment in Germany (2015–2023): nationwide trends in thrombolysis and thrombectomy by age and sex. Brain Sci2025; 15: 832.
4.
GajurelBPNepalGJaiswalV, et al. Utilization rates of intravenous thrombolysis for acute ischemic stroke in Asian countries: a systematic review and meta-analysis. Medicine2023; 102: Article e35560.
5.
LiptonP.Ischemic cell death in brain neurons. Physiol Rev1999; 79: 1431–1568.
6.
McKennaMCWaagepetersenHSSchousboeA, et al. Neuronal and astrocytic shuttle mechanisms for cytosolic–mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. Biochem Pharmacol2006; 71: 399–407.
7.
RejR.Measurement of aspartate aminotransferase activity: effects of oxamate. Clin Chem1979; 25: 555–559.
8.
RejR.Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin Chem1978; 24: 1971–1979.
9.
FerréPWilliamsonDH.Evidence for the participation of aspartate aminotransferase in hepatic glucose synthesis in the suckling newborn rat. Biochem J1978; 176: 335–338.
10.
FahienLAMacDonaldMJ.The succinate mechanism of insulin release. Diabetes2002; 51: 2669–2676.
11.
Plee-GautierEGrimalHAggerbeckM, et al. Cytosolic aspartate aminotransferase gene is a member of the glucose-regulated protein gene family in adipocytes. Biochem J1998; 329: 37–40.
12.
AkagiR.Purification and characterization of cysteine aminotransferase from rat liver cytosol. Acta Med Okayama1982; 36: 187–197.
13.
ZhangDXiaoMWangL, et al. Blood-based glutamate scavengers reverse traumatic brain injury-induced synaptic plasticity disruption by decreasing glutamate level in hippocampus interstitial fluid, but not cerebral spinal fluid, in vivo. Neurotox Res2018; 35: 360–372.
14.
RubanAMoharBJonaG, et al. Blood glutamate scavenging as a novel neuroprotective treatment for paraoxon intoxication. J Cereb Blood Flow Metab2013; 34: 221–227.
15.
RubanACohen-Kashi MalinaKCooperI, et al. Combined treatment of an amyotrophic lateral sclerosis rat model with recombinant GOT1 and oxaloacetic acid: a novel neuroprotective treatment. Neurodegener Dis2015; 15: 233–242.
16.
RubanABerkutzkiTCooperI, et al. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest New Drugs2012; 30: 2226–2235.
17.
ZhangDQiYKlyubinI, et al. Targeting glutamatergic and cellular prion protein mechanisms of amyloid β-mediated persistent synaptic plasticity disruption: longitudinal studies. Neuropharmacology2017; 121: 231–246.
18.
Pérez-MatoMRamos-CabrerPSobrinoT, et al. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis2014; 5: e992–e992.
19.
BoykoMGruenbaumSEGruenbaumBF, et al. Brain to blood glutamate scavenging as a novel therapeutic modality: a review. J Neural Transm2014; 121: 971–979.
20.
BoykoMStepenskyDGruenbaumBF, et al. Pharmacokinetics of glutamate–oxaloacetate transaminase and glutamate–pyruvate transaminase and their blood glutamate-lowering activity in naïve rats. Neurochem Res2012; 37: 2198–2205.
21.
CastilloJLozaMIMirelmanD, et al. A novel mechanism of neuroprotection: blood glutamate grabber. J Cereb Blood Flow Metab2015; 36: 292–301.
22.
RinkCGnyawaliSPetersonL, et al. Oxygen-inducible glutamate oxaloacetate transaminase as protective switch transforming neurotoxic glutamate to metabolic fuel during acute ischemic stroke. Antioxid Redox Signal2011; 14: 1777–1785.
23.
KhannaSBriggsZRinkC.Inducible glutamate oxaloacetate transaminase as a therapeutic target against ischemic stroke. Antioxid Redox Signal2015; 22: 175–186.
24.
RinkCGnyawaliSStewartR, et al. Glutamate oxaloacetate transaminase enables anaplerotic refilling of TCA cycle intermediates in stroke-affected brain. FASEB J2017; 31: 1709–1718.
25.
XuJKhouryNJacksonCW, et al. Ischemic neuroprotectant PKCε restores mitochondrial glutamate oxaloacetate transaminase in the neuronal NADH shuttle after ischemic injury. Transl Stroke Res2019; 11: 418–432.
26.
Pérez-MatoMDopico-LópezAAkkocY, et al. Preclinical validation of human recombinant glutamate–oxaloacetate transaminase for the treatment of acute ischemic stroke. iScience2024; 27: 111108.
27.
VesterinenHMSenaESEganKJ, et al. Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods2014; 221: 92–102.
28.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
29.
LeenaarsMHooijmansCRvan VeggelN, et al. A step-by-step guide to systematically identify all relevant animal studies. Lab Anim2012; 46: 24–31.
30.
HaddawayNRGraingerMJGrayCT.Citationchaser: a tool for transparent and efficient forward and backward citation chasing in systematic searching. Res Synth Methods2022; 13: 533–545.
31.
McCannSKCramondFMacleodMR, et al. Systematic review and meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke: an update. Transl Stroke Res2016; 7: 395–406.
32.
FisherMFeuersteinGHowellsDW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke2009; 40: 2244–2250.
33.
SenaEvan der WorpHBHowellsD, et al. How can we improve the pre-clinical development of drugs for stroke?. Trends Neurosci2007; 30: 433–439.
34.
CamposFSobrinoTRamos-CabrerP, et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab2011; 31: 1378–1386.
35.
ChenSSunMZhaoX, et al. Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis. Mol Med Rep2019; 19: 3009–3020.
36.
Dopico-LópezAPérez-MatoMda Silva-CandalA, et al. Inhibition of endogenous blood glutamate oxaloacetate transaminase enhances the ischemic damage. Transl Res2021; 230: 68–81.
37.
KhannaSStewartRGnyawaliS, et al. Phytoestrogen isoflavone intervention to engage the neuroprotective effect of glutamate oxaloacetate transaminase against stroke. FASEB J2017; 31: 4533–4544.
38.
KnappLGellértLKocsisK, et al. Neuroprotective effect of oxaloacetate in a focal brain ischemic model in the rat. Cell Mol Neurobiol2015; 35: 17–22.
39.
NagyDMarosiMKisZ, et al. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol2009; 29: 827–835.
40.
WangYGuanXGaoCL, et al. Medioresinol as a novel PGC-1α activator prevents pyroptosis of endothelial cells in ischemic stroke through PPARα–GOT1 axis. Pharmacol Res2021; 169: 105640.
41.
ZaghmiADopico-LópezAPérez-MatoM, et al. Sustained blood glutamate scavenging enhances protection in ischemic stroke. Commun Biol2020; 3: 729.
42.
López-MoralesMACastelló-RuizMBurgueteMC, et al. Effect and mechanisms of resveratrol in animal models of ischemic stroke: a systematic review and Bayesian meta-analysis. J Cereb Blood Flow Metab2023; 43: 2013–2028.
43.
HeoJHHanSWLeeSK.Free radicals as triggers of brain edema formation after stroke. Free Radic Biol Med2005; 39: 51–70.
44.
BaiJLydenPD.Revisiting cerebral postischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema. Int J Stroke2015; 10: 143–152.
45.
LeeSYLimJYKangEK, et al. Prediction of good functional recovery after stroke based on combined motor and somatosensory evoked potential findings. J Rehabil Med2010; 42: 16–20.
46.
SaverJL.Targeting the brain: neuroprotection and neurorestoration in ischemic stroke. Pharmacotherapy2010; 30: 62S–69S.
47.
LydenPDBosettiFDinizMA, et al. The Stroke Preclinical Assessment Network: rationale, design, feasibility, and stage 1 results. Stroke2022; 53: 1802–1812.
48.
CrossleyNASenaEGoehlerJ, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke2008; 39: 929–934.
49.
Aliena-ValeroABaixauli-MartínJCastelló-RuizM, et al. Effect of uric acid in animal models of ischemic stroke: a systematic review and meta-analysis. J Cereb Blood Flow Metab2021; 41: 707–722.
50.
PatelRBKumskovaMKodaliH, et al. Uric acid stroke cerebroprotection transcended sex, age, and comorbidities in a multicenter preclinical trial. Stroke2025; 56: 965–973.
51.
Correa-PazCLópez-AriasEPérez-MatoM, et al. Protective recombinant glutamate oxaloacetate transaminase increases the benefits of alteplase recanalization therapy in experimental ischaemic stroke. J Cereb Blood Flow Metab2026. Online ahead of print 2026.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
